Compare Merck & Co., Inc. (MRK) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs WD 40 Company — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while WD 40 Company trades at $237.72 (market cap $3.22B). The key difference: Merck & Co., Inc. is far larger — about 95.4× WD 40 Company's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | WDFC | |
|---|---|---|
Market Cap | $307.25B | $3.22B |
Sector | Health | Technology |
52-Week High | $129.52 | $264.91 |
52-Week Low | $77.60 | $187.52 |
Enterprise Value | $350.66B | $3.27B |
Dividend Yield | 2.73% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
WDFC trades at $239.59, down 2.92% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, and maintains solid profitability with a 13.22% net income margin. Recent news highlights its brand strength and efficient operations, though some analysts see limited upside.
The outlook is balanced: earnings beats and a strong brand provide support, but high valuation multiples (P/E 36.44) and mixed analyst sentiment (71.42% hold rating) suggest cautious optimism. Key risks include margin pressure from input costs and competitive challenges, requiring careful monitoring of future earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
